SCHEMBL533005

SCHEMBL533005

Cc1cc(C)c(N2CCNCC2)c(C)c1N

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 7/20 0.44
HRH4 Q9H3N8 2/20 0.40
ALDH1A1 P00352 2/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTR3A P46098 2/20 0.39
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
HTR3D Q70Z44 1/20 0.39
HTR3C Q8WXA8 1/20 0.39
HTR1A P08908 1/20 0.38
CCR4 P51679 1/20 0.38
LMNA P02545 1/20 0.38
HTR2C P28335 1/20 0.38
ADRB2 P07550 1/20 0.38
HTR7 P34969 2/20 0.38
IKBKB O14920 1/20 0.37
NCF1 P14598 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL532945 0.85 ALDH1A1 (0.42) HRH4ALDH1A1MAPTSMN1; SMN2IKBKB
SCHEMBL531525 0.83 ALDH1A1 (0.41) ALDH1A1MAPTSMN1; SMN2LMNAIKBKB
SCHEMBL14313774 0.81 ADRA2C (0.41) HRH4ALDH1A1MAPT
SCHEMBL6560441 0.80 ADRB1 (0.50) ADRB1ALDH1A1HTR3AHTR3EHTR3B
SCHEMBL1200351 0.80 HPGD (0.49) ALDH1A1MAPTSMN1; SMN2IKBKB
SCHEMBL14313773 0.79 ALDH1A1 (0.41) ALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL2366412 0.76 ADRB1 (0.50) ADRB1ALDH1A1MAPTSMN1; SMN2HTR3A
SCHEMBL15305246 0.74 ADRB1 (0.44) ADRB1ALDH1A1HTR3AHTR3EHTR3B
SCHEMBL16795346 0.74 ADRB2 (0.42) ADRB1HRH4ALDH1A1ADRB2
SCHEMBL28905291 0.73 ADRB1 (0.47) ADRB1ALDH1A1HTR3AHTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2415760-A2 CCR-9 antagonists ENCYSIVE PHARMACEUTICALS, INC. (US) 2012-02-08 EP disclosed
US-7579340-B2 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists PFIZER INC (US) 2009-08-25 US disclosed
US-7319111-B2 Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-01-15 US disclosed
US-20070293503-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists ENCYSIVE PHARMACEUTICALS, INC. 2007-12-20 US disclosed
US-7288538-B2 Cardiovascular homeostasis through combination of direct neuronal control and systemic neurohormonal activation ENCYSIVE PHARMACEUTICALS, INC. (US) 2007-10-30 US disclosed
US-20050049286-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists ENCYSIVE PHARMACEUTICALS INC. 2005-03-03 US disclosed
US-20040180892-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists ENCYSIVE PHARMACEUTICALS INC. 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049286-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists CCR9, CCR1, CCRL2 ADRB1 220/4885HRH4 173/4885ALDH1A1 3281/4885
US-20040180892-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists CCR9, CCR1, CCRL2 ADRB1 220/4885HRH4 173/4885ALDH1A1 3281/4885
US-20070293503-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists CCR9, CCR1, CCRL2 ADRB1 220/4885HRH4 173/4885ALDH1A1 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.